Vir Biotechnology (NASDAQ:VIR) Director Sells $124,080.00 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki Sato sold 22,000 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $5.64, for a total value of $124,080.00. Following the completion of the sale, the director owned 1,210,391 shares in the company, valued at approximately $6,826,605.24. This represents a 1.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Vir Biotechnology Trading Down 5.4%

Shares of Vir Biotechnology stock traded down $0.31 during trading hours on Tuesday, reaching $5.30. 638,909 shares of the company’s stock were exchanged, compared to its average volume of 1,539,719. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $14.45. The firm has a market capitalization of $735.56 million, a price-to-earnings ratio of -1.32 and a beta of 1.27. The company has a fifty day moving average of $5.51 and a 200-day moving average of $5.31.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). The business had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $2.38 million. Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The company’s revenue for the quarter was down 60.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.02) EPS. On average, equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

VIR has been the topic of a number of recent research reports. Evercore ISI initiated coverage on shares of Vir Biotechnology in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 target price on the stock. Bank of America upgraded shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $12.00 to $14.00 in a research report on Wednesday, August 27th. Raymond James Financial assumed coverage on shares of Vir Biotechnology in a research note on Friday, July 11th. They set an “outperform” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Tuesday, October 14th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a research report on Monday, September 15th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vir Biotechnology presently has an average rating of “Moderate Buy” and a consensus price target of $17.30.

Institutional Investors Weigh In On Vir Biotechnology

Large investors have recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new stake in shares of Vir Biotechnology during the second quarter worth $35,000. GAMMA Investing LLC lifted its stake in shares of Vir Biotechnology by 524.3% during the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock worth $46,000 after buying an additional 5,972 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of Vir Biotechnology by 153.8% during the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after buying an additional 4,899 shares during the last quarter. Apollon Wealth Management LLC bought a new stake in Vir Biotechnology in the 2nd quarter valued at about $50,000. Finally, Daiwa Securities Group Inc. boosted its holdings in Vir Biotechnology by 2,200.6% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock valued at $62,000 after purchasing an additional 11,773 shares during the period. Institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).